Barclays Bank PLC Publication of Supplement (6238H)
2023年7月29日 - 2:05AM
RNSを含む英国規制内ニュース (英語)
TIDM33JE
RNS Number : 6238H
Barclays Bank PLC
28 July 2023
Publication of Supplement
The following supplement has been approved by the Financial
Conduct Authority and the International Securities Market and is
available for viewing:
Supplement 1 dated 28 July 2023 (the "Supplement") to the FCA
Registration Document dated 6 March 2023 for the Barclays Bank PLC
(the "Registration Document").
Please read the disclaimer below "Disclaimer - Intended
Addressees" before attempting to access this service, as your right
to do so is conditional upon complying with the requirements set
out below.
To view the full document, please paste the following URL into
the address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/6238H_1-2023-7-28.pdf
A copy of the above document has been submitted to the National
Storage Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
Barclays Treasury
1 Churchill Place
Canary Wharf
London E14 5HP
DISCLAIMER - INTENDED ADDRESSEES
IMPORTANT: You must read the following before continuing: The
following applies to the Supplement available by clicking on the
link above, and you are therefore advised to read this carefully
before reading, accessing or making any other use of the
Supplement. In accessing the Supplement, you agree to be bound by
the following terms and conditions, including any modifications to
them, any time you receive any information from us as a result of
such access.
NEITHER THE SUPPLEMENT NOR THE REGISTRATION DOCUMENT MAY NOT BE
FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT
BE REPRODUCED IN ANY MANNER WHATSOEVER. THE SUPPLEMENT AND/OR THE
REGISTRATION DOCUMENT MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED
STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN, AND IN
RELIANCE ON, REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE "SECURITIES ACT"). ANY FORWARDING, DISTRIBUTION OR
REPRODUCTION OF THE SUPPLEMENT AND/OR THE REGISTRATION DOCUMENT IN
WHOLE OR IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE
MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE
LAWS OF OTHER JURISDICTIONS.
NOTHING IN THIS ELECTRONIC PUBLICATION OR IN THE SUPPLEMENT OR
THE REGISTRATION DOCUMENT CONSTITUTES AN OFFER OF SECURITIES FOR
SALE IN ANY JURISDICTION. THE NOTES HAVE NOT BEEN, AND WILL NOT BE,
REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES OR OTHER JURISDICTION.
Please note that the information contained in the Supplement may
be addressed to and/or targeted at persons who are residents of
particular countries (as specified in the Registration Document)
only and is not intended for use and should not be relied upon by
any person outside these countries and/or to whom any offer of
Notes is not addressed. Prior to relying on the information
contained in the Supplement and/or the Registration Document you
must ascertain whether or not you are part of the intended
addressees of the information contained therein.
Confirmation of your Representation: In order to be eligible to
view the Supplement and/or the Registration Document or make an
investment decision with respect to the Notes, you must be a person
other than a U.S. person (within the meaning of Regulation S under
the Securities Act). By accessing the Supplement and/or the
Registration Document, you shall be deemed to have represented that
you and any customers you represent are not U.S. persons (as
defined in Regulation S to the Securities Act), and that you
consent to delivery of the Supplement and any supplements thereto
via electronic publication.
You are reminded that the Supplement has been made available to
you on the basis that you are a person into whose possession the
Supplement and/or the Registration Document may be lawfully
delivered in accordance with the laws of the jurisdiction in which
you are located and you may not, nor are you authorised to, deliver
the Supplement and/or the Registration Document to any other
person.
The Supplement and/or the Registration Document does not
constitute, and may not be used in connection with, an offer or
solicitation in any place where offers or solicitations are not
permitted by law. If a jurisdiction requires that the offering be
made by a licensed broker or dealer and the underwriters or any
affiliate of the underwriters is a licensed broker or dealer in
that jurisdiction, the offering shall be deemed to be made by the
underwriters or such affiliate on behalf of the issuer in such
jurisdiction. Under no circumstances shall the Supplement and/or
the Registration Document constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of any
Notes issued or to be issued pursuant to the Supplement and/or the
Registration Document, in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
The Supplement has been made available to you in an electronic
form. You are reminded that documents transmitted via this medium
may be altered or changed during the process of electronic
transmission and consequently none of the issuer, its advisers nor
any person who controls any of them nor any director, officer,
employee nor agent of it or affiliate of any such person accepts
any liability or responsibility whatsoever in respect of any
difference between the Supplement made available to you in
electronic format and the hard copy version available to you on
request from the issuer.
Your right to access this service is conditional upon complying
with the above requirement.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PSPNKFBKABKDPOB
(END) Dow Jones Newswires
July 28, 2023 13:05 ET (17:05 GMT)
Barclays Nts45 (LSE:33JE)
過去 株価チャート
から 9 2024 まで 10 2024
Barclays Nts45 (LSE:33JE)
過去 株価チャート
から 10 2023 まで 10 2024